Figure 1(b) presents the PLP2 expression in 8 molecular subgroups, showing that elevated PLP2 expression was prevalent in 3 known to confer high risk in terms of clinical outcome and course: proliferation (PR), MAF/MAFB (MF), and MMSET/FGGR3 (MS) (p < 0.001). These findings prompted us to confirm that PLP2 is a high-risk gene in MM. This evidence concerns the gene NSD2 and Miyoshi myopathy.